These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311 [TBL] [Abstract][Full Text] [Related]
9. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease. Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M; Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085 [TBL] [Abstract][Full Text] [Related]
10. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028 [TBL] [Abstract][Full Text] [Related]
11. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
12. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Jovicich J; Babiloni C; Ferrari C; Marizzoni M; Moretti DV; Del Percio C; Lizio R; Lopez S; Galluzzi S; Albani D; Cavaliere L; Minati L; Didic M; Fiedler U; Forloni G; Hensch T; Molinuevo JL; Bartrés Faz D; Nobili F; Orlandi D; Parnetti L; Farotti L; Costa C; Payoux P; Rossini PM; Marra C; Schönknecht P; Soricelli A; Noce G; Salvatore M; Tsolaki M; Visser PJ; Richardson JC; Wiltfang J; Bordet R; Blin O; Frisoniand GB; J Alzheimers Dis; 2019; 69(1):15-35. PubMed ID: 30400088 [TBL] [Abstract][Full Text] [Related]
13. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW; Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S; Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118 [TBL] [Abstract][Full Text] [Related]
15. Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. van Maurik IS; Zwan MD; Tijms BM; Bouwman FH; Teunissen CE; Scheltens P; Wattjes MP; Barkhof F; Berkhof J; van der Flier WM; JAMA Neurol; 2017 Dec; 74(12):1481-1491. PubMed ID: 29049480 [TBL] [Abstract][Full Text] [Related]
16. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648 [TBL] [Abstract][Full Text] [Related]
17. Clinical Utility of Cerebrospinal Fluid Aβ42 and Tau Measures in Diagnosing Mild Cognitive Impairment in Early Onset Dementia. Hosseini AA; Brown T; Mannino L; Gran B; Junaid K; Mukaetova-Ladinska EB J Alzheimers Dis; 2022; 87(2):771-780. PubMed ID: 35404281 [TBL] [Abstract][Full Text] [Related]
18. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. van Waalwijk van Doorn LJ; Gispert JD; Kuiperij HB; Claassen JA; Arighi A; Baldeiras I; Blennow K; Bozzali M; Castelo-Branco M; Cavedo E; Emek-Savaş DD; Eren E; Eusebi P; Farotti L; Fenoglio C; Ormaechea JF; Freund-Levi Y; Frisoni GB; Galimberti D; Genc S; Greco V; Hampel H; Herukka SK; Liu Y; Lladó A; Lleó A; Nobili FM; Oguz KK; Parnetti L; Pereira J; Picco A; Pikkarainen M; de Oliveira CR; Saka E; Salvadori N; Sanchez-Valle R; Santana I; Scarpini E; Scheltens P; Soininen H; Tarducci R; Teunissen C; Tsolaki M; Urbani A; Vilaplana E; Visser PJ; Wallin AK; Yener G; Molinuevo JL; Meulenbroek O; Verbeek MM J Alzheimers Dis; 2017; 56(2):543-555. PubMed ID: 28059783 [TBL] [Abstract][Full Text] [Related]
19. Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. Devanarayan P; Devanarayan V; Llano DA; J Alzheimers Dis; 2019; 68(2):537-550. PubMed ID: 30775985 [TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]